Skip to main content
. Author manuscript; available in PMC: 2012 Jul 29.
Published in final edited form as: Chem Biol. 2011 Jul 29;18(7):846–856. doi: 10.1016/j.chembiol.2011.05.009

Figure 3. Pharmacological and shRNA blockade of MAGL impairs PC3 aggressiveness.

Figure 3

(A–C, D–F) Both shMAGL and JZL184 (1 µM) PC3 cells show impaired migration (A, D), invasion (B, E), and serum-free survival (C, F). Cancer cells were pretreated with JZL184 in serum-free media for 4 h before migration (5 h migration time) and invasion (24 h invasion time) assays and 24 h before cell survival (20 h in serum and 4 h in serum-free media with JZL184). For PC3 migration, representative fields of migrated cells are shown at 200 × magnification. (G) Pharmacological (40 mg/kg JZL184, daily oral gavage) inhibition of MAGL causes impairments in PC3 tumor xenograft growth in immune-deficient SCID mice. Representative tumors are shown on the right. **p<0.01 for shMAGL versus shControl or JZL184 versus vehicle treatment groups. Data are presented as means ± SEM. For (A,B,D,E), n=4–5/group and for (C,F,G), n=6–8/group. See Figure S2 and Figure S3.